Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses various therapeutic options for alopecia areata and reports no new clinical results; treatments may manage symptoms but do not cure the condition.

This review presents clinical and preclinical evidence supporting innovative regenerative approaches to treat vitiligo, as existing treatments lack a specific cure and predictable long-term repigmentation outcomes.

This review outlines the advancements in organ and tissue transplantation since the discovery of the human MHC and reports no new clinical results.

Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.

This research paper reviews the mechanisms and management of non-biologic immunosuppressive drugs used in dermatology, highlighting their safety profiles and handling during pregnancy, breastfeeding, and vaccination, but does not report specific results on these aspects.

This study reported that intensive immunosuppression in multiple sclerosis patients significantly reduced relapse rates versus pre-treatment expectations, though some required ongoing treatment after tapering.

This review examines nonmalignant skin toxicities from immunosuppressive and transplant-related medications, emphasizing the need for effective identification and management by care providers; it presents no new research findings.

This study observed that dermatological patients using certain immunosuppressants, like azathioprine and high-dose prednisolone, had a reduced humoral immune response to the Sinovac-CoronaVac COVID-19 vaccine compared to those without such treatments.

This article provides a detailed analysis of immunosuppressive medications in transplant patients and discusses the increased risk of skin cancer, but it reports no new experimental results.

This review discusses the use, mechanism, and side effects of topical immunomodulators in treating immune-mediated skin disorders and reports no new clinical results, urging further research on experimental agents.

This review discusses cyclosporine A's mechanisms of action and side effects compared to tacrolimus in renal transplantation, but it reports no new experimental results; the authors highlight implications for cardiovascular risk management.

This report describes a case of polymyositis that was resistant to steroids and immunosuppressants but showed improvement with immunoadsorption therapy.

In this reported case, an immunosuppressive regimen including tacrolimus and mycophenolate mofetil was associated with a total regression of hidradenitis suppurativa activity over one year, while cyclosporine alone had no effect.

Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.

Immunosuppression therapy with methylprednisolone effectively treats childhood alopecia areata.

This source does not report original research findings but reviews the mechanisms and challenges of immune response and immunosuppressive management in liver transplantation.

This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.

This case report describes an autoimmune hepatitis patient who achieved remission with mycophenolate mofetil and corticosteroids after intolerance to azathioprine-based therapy.

This review discusses the complex pathophysiological and clinical aspects of COVID-19, including dermatological findings and their association with SARS-CoV-2 infection but reports no new clinical results.

The authors concluded that some patients clinically diagnosed with telogen effluvium may actually have alopecia areata incognita, suggested by the presence of dystrophic hairs and development of alopecia patches.

This study found that topical application of cyclosporin A and FK506 induces new hair growth in mice, while ascomycin and rapamycin do not, suggesting hair induction is not due to immunosuppression.

This study found that the oral IRAK4-inhibitors BAY 1834845 and BAY 1830839 reduced skin inflammation and systemic inflammatory responses in healthy volunteers, showing similar pharmacodynamic effects to prednisolone when challenged with topical imiquimod and intravenous LPS.

This report describes two renal transplant patients whose hair loss improved after switching from tacrolimus to cyclosporine, suggesting that cyclosporine might counteract steroid-induced alopecia.

The authors concluded that incorporating routine endocrinology consultations into transplant care could address CNI-related endocrine toxicities, but prospective studies are needed to assess the impact on graft and patient survival.

Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.

This study suggests that cyclosporine may directly affect epithelial cell growth, potentially leading to broader use of its nonimmunosuppressive analogues in treating hyperproliferative epidermal diseases.

This review discusses the range of cutaneous immune-related adverse events induced by immune checkpoint inhibitors and the proposed mechanisms underlying these skin reactions, but reports no new clinical results.

This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.

Prednisone has risks for lupus patients, isotretinoin is safe for mental health, transplant patients risk skin cancer, and various treatments are effective for specific skin conditions.

This case report highlights hair loss as a side effect of tacrolimus-based immunosuppression in a kidney transplant patient, improving after switching to cyclosporine A. The authors emphasize the importance of monitoring and managing such side effects to ensure treatment adherence and patient well-being.